Andy Lin's Long-term Stock Investment Blog

Akeso’s lung cancer drug beat world best-selling drug, a biotech DeepSeek watershed

Akeso’s Ivonescimab performed better than world best selling drug Keytruda in treating patients with advanced lung cancer.

Welcome to leave a message or opinions. But do not have wrong expectations on this site─── we don't tout stocks, no commercials, do not ask whether individual stocks or specific industries are worth buying, individual stock prices, price hints, and stock price predictions; such messages or offenders will be deleted.
The content of this site is the author’s personal opinions and is for reference only. I am not responsible for the correctness, opinions, and immediacy of the content and information of the article. Readers must make their own judgments.
I shall not be liable for any damages or other legal liabilities for any direct or indirect losses caused by readers directly or indirectly relying on and referring to the information on this site, or any liability arising therefrom.
Please do not promote any companies, stocks, or commodities on this site.
Readers can use this link to contact me directly.

error: Content is protected !!